Trial Profile
Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn's Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors UCB
- 03 Apr 2022 Status changed from recruiting to completed.
- 10 Jun 2011 New trial record